Keywords: ablynx, loss, deepens, 3m, euros, belgian, biopharmaceutical
Ablynx' loss deepens 21.6% to 14.3M euros
Article | 23 March 2009
Belgian biopharmaceutical firm Ablynx' full-year 2008 loss deepened 21.6% on the year before to 15.2 million euros ($19.2 million), as the deficit from continuing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
